RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Talecris Biotherapeutics, Inc., makers of Gamunex®, today announced results from a new survey showing that Gamunex® is the preferred liquid immune globulin intravenous (IGIV), among allergists and immunologists. By a statistically significant margin (p< 0.05) Gamunex® is preferred over the three other available liquid IGIV preparations.
